Report: U.S. Therapeutic Monoclonal Antibodies Markets TOC

1. Executive Summary

2. Objectives and Scope

1. Objectives and Scope
- 1. Objectives
- 2. Scope

3. Introduction to Monoclonal Antibodies

1. Monoclonal Antibodies Market Overview
- 1. Introduction
- 2. Structure of Antibodies
- 3. Typical Problems with Murine mAbs
- 4. The Role of Hybridoma Clone
- 5. Medical Utility of mAbs
- 6. Market Overview
2. Evolution and Technology Trends
- 1. Introduction
- 2. Early Murine mAbs
- 3. Chimeric mAbs
- 4. Humanized mAbs
- 5. Fully Human mAbs
- 6. Phage Display of Human mAbs
- 7. Monoclonal Antibodies as Carriers
- 8. Naked Monoclonal Antibodies
- 9. Conjugated Monoclonal Antibodies
3. Future of Monoclonal Antibodies
- 1. The Foundation for Optimistic Future
- 2. Return on Investment and Future

4. Industry Challenges

1. Challenges Affecting the US Therapeutic Monoclonal Antibodies Market
- 1. Introduction
- 2. Increasing Costs and Complexities of Clinical Trials
- 3. Long-Term Safety and Efficacy
- 4. High Cost of mAbs
- 5. Restricted Government Healthcare Spending
- 6. Complexities of Registration Processes
- 7. Production Capacity Crunch
- 8. Identify New Targets or Access Validated Targets
- 9. Small Molecule Drugs
- 10. Second Line to First Line Therapy
- 11. Production Challenges of Humanized and Human mAbs

5. Pipeline Analysis

1. Overview of the mAbs Pipeline
- 1. Introduction
- 2. Therapeutic mAbs in Oncology
- 3. Therapeutic mAbs in Autoimmune and Inflammatory Disorders
- 4. Therapeutic mAbs in Organ Transplants
- 5. Therapeutic mAbs in Cardiovascular Disorders
- 6. Therapeutic mAbs in Infectious Diseases
- 7. Therapeutic mAbs in Miscellaneous Indications
- 8. Participants in mAB Development and/or Marketing

6. Total US Therapeutic Monoclonal Antibodies Market

1. Market Dynamics
- 1. Introduction
- 2. Market Engineering Measurement
- 3. Market Drivers
  - a. Paucity of Reliable Conventional Therapies in Serious and/or Long-term Illnesses Propels the Market for Therapeutic mAbs
  - b. Highly Specific Actions of mAbs Make Them Attractive as Therapeutics and Drive Market Expansion
  - c. Improved Safety and Tolerance Profiles of mAbs Expand Their Applications
  - d.Widening Indication Range of Therapeutic mAbs Adds New Patient Groups
  - e.Evolution of Therapeutic mAbs from Murine and Chimeric to Humanized and Human Forms Limits Immunogenicity While Expanding Usage
  - f. Market Growth Impelled as Therapeutic Monoclonal Antibodies Improve Survival Rates Much Better than Small-molecule Drugs
  - g. Strategic Partnerships of Big Pharma With mAb Developers Boost Market Performance
  - h. Mainly Long-term Illnesses Needing Constant Therapeutic Intervention Maintains Therapeutic mAbs Demand
- 4. Market Restraints
  - a. High Cost of Therapeutic mAbs Delays Demand and Growth
  - b. Paucity of Validated Targets Restricts Patient Numbers and Curbs Market Potential
  - c. Robust Competition from Optional Therapies Curtails mAb Acceptance
  - d.Lack of Large Databases of Long-term Safety Curbs Demand
  - e.Need for Comparative Studies of mAbs with Optional Therapies Discourages Uptake
  - f. High Risks of Product Development Contain mAbs Market Expansion
2. Market Forecasts
- 1. Forecast Assumptions
- 2. Total Revenue Forecasts
- 3. Segment-wise Revenue Forecasts
- 4. Issue of Pricing and Reimbursements
3. Frost and Sullivan Awards
- 1. Technology Excellence Award
- 2. Entrepreneurial Company Award
- 3. Competitive Strategy Leadership Award
- 4. Growth Strategy Leadership Award
- 5. Industry Innovation and Advancement Award
- 6. Technology Innovation Award

7. Competitive Analysis

1. Competitive Structure
- 1. Competitive Factors
- 2. Companies in Therapeutic mAbs Research
- 3. Companies in Marketing and Sales of Therapeutic mAbs
- 4. The Dynamism of Deals
- 5. Market Share Analysis

8. US Therapeutic Monoclonal Antibodies for Use in Oncology

1. Overview
- 1. Introduction
- 2. Market Engineering Measurement
2. Market Forecasts
- 1. Revenue Forecasts
3. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis
- 3. Competitive Factors

9. US Therapeutic Monoclonal Antibodies in Autoimmune and Inflammatory Disorders

1. Overview
- 1. Introduction
- 2. Market Engineering Measurement
2. Market Forecasts
- 1. Revenue Forecasts
3. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis
- 3. Competitive Factors

10. US Therapeutic Monoclonal Antibodies for Use in Organ Transplants

1. Overview
- 1. Introduction
- 2. Market Engineering Measurement
2. Market Forecasts
- 1. Revenue Forecasts
3. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis

11. US Therapeutic Monoclonal Antibodies for Use in Cardiovascular Disorders

1. Overview
- 1. Introduction
- 2. Market Engineering Measurement
2. Market Forecasts
- 1. Revenue Forecasts
3. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis

12. US Therapeutic Monoclonal Antibodies for Use in Infectious Diseases

1. Overview
- 1. Introduction
- 2. Market Engineering Measurement
2. Market Forecasts
- 1. Revenue Forecasts
3. Competitive Analysis
- 1. Competitive Structure
- 2. Market Share Analysis

13. Market Engineering Strategy for the US Therapeutic Monoclonal Antibodies Market

1. Strategic Recommendations
- 1. Introduction
- 2. Market Life Cycle
- 3. Skills Required to be Successful - Strengths Pyramid
- 4. Seven Ways to Growth
- 5. Strategies for Success for mAb Industry Participants

14. Decision Support Databases

1. Oncology Databases
- 1. Prostate Cancer
- 2. Breast Cancer
- 3. Bladder Cancer
- 4. Colon Rectum Cancer
- 5. Lung Cancer
- 6. Stomach Cancer
- 7. Liver Cancer
2. Autoimmune and Inflammatory Disorders Databases
- 1. Arthritis
- 2. Multiple Sclerosis
3. Organ Transplant Databases
- 1. Major Organ Transplants
- 2. Heart Transplants
- 3. Kidney Transplants
- 4. Pancreas Transplants
- 5. Liver Transplants
- 6. Lung Transplants
4. Cardiovascular Databases
- 1. Cardiologists
- 2. Hypertension
- 3. Stroke
- 4. Myocardial Infarction

List Of Figures

Chapter 3

*
Introduction to Monoclonal Antibodies
*
Therapeutic Monoclonal Antibodies Market:
*
Marketed Brands (US), 2005

Chapter 4

Challenges Affecting the US Therapeutic Monoclonal Antibodies Market
Therapeutic Monoclonal Antibodies Market:
Industry Challenges Ranked by Priority (US), 2005
Therapeutic Monoclonal Antibodies Market:
Impact of Industry Challenges (US), 2005-2012

Chapter 5

Pipeline Analysis of the US Therapeutic Monoclonal Antibodies Market
Therapeutic Monoclonal Antibodies Market:
Pipeline Marketed Brands New Oncology Indications (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs in Oncology (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline Marketed Brands New AIID Indications (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs in AIID (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs in Transplants (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs / Indications in Cardiology (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs in Infections (US), 2005
Therapeutic Monoclonal Antibodies Market:
Pipeline New mAbs in Other Indications (US), 2005

Chapter 6

Analysis of the US Therapeutic Monoclonal Antibodies Market
Therapeutic Monoclonal Antibodies Market:
Market Drivers Ranked by Priority (US), 2005
Therapeutic Monoclonal Antibodies Market:
Impact of Market Drivers (US), 2005-2012
Therapeutic Monoclonal Antibodies Market:
Market Restraints Ranked by Priority (US), 2005
Therapeutic Monoclonal Antibodies Market:
Impact of Market Restraints (US), 2005-2012
Therapeutic Monoclonal Antibiotics Market:
Revenue Forecasts (US), 2002-2012
Therapeutic Monoclonal Antibiotics Market:
Products Offered by Major Market Participants (US), 2005
Therapeutic Monoclonal Antibiotics Market:
Segment-wise Revenue Forecasts (US), 2002-2012
Therapeutic Monoclonal Antibiotics Market:
Prices and Costs of Marketed Brands (US), 2005

Chapter 7

Competitive Analysis of the US Therapeutic Monoclonal Antibodies Market
Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005
Therapeutic Monoclonal Antibodies Market:
Deals, Sample List (US), 2005
Therapeutic Monoclonal Antibodies Market:
Market Players Ranked in Order of Market Position (US), 2005

Chapter 8

US Therapeutic Monoclonal Antibodies Market for Use in Oncology
Oncology Therapeutic Monoclonal Antibodies Market:
Revenue Forecasts (US), 2002-2012
Oncology Therapeutic Monoclonal Antibodies Market:
Marketed Brands (US), 2005
Oncology Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005
Oncology Therapeutic Monoclonal Antibodies Market:
Market Players Ranked in Order of Market Position (US), 2005

Chapter 9

US Therapeutic Monoclonal Antibodies Market for Use in Autoimmune and Inflammatory Diseases
AIID Therapeutic Monoclonal Antibodies Market:
Revenue Forecasts (US), 2002-2012
AIID Therapeutic Monoclonal Antibodies Market:
Marketed Brands (US), 2005
AIID Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005
Oncology Therapeutic Monoclonal Antibodies Market:
Market Players Ranked in Order of Market Position (US), 2005

Chapter 10

US Therapeutic Monoclonal Antibodies Market for Use in Organ Transplants
Organ Transplants Therapeutic Monoclonal Antibodies Market:
Revenue Forecasts (US), 2002-2012
Organ Transplants Therapeutic Monoclonal Antibodies Market:
Marketed Brands (US), 2005
Organ Transplants Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005

Chapter 11

US Therapeutic Monoclonal Antibodies Market for Use in Cardiovascular Disorders
Cardiovascular Disorders Therapeutic Monoclonal Antibodies Market:
Revenue Forecasts (US), 2002-2012
Cardiovascular Disorders Therapeutic Monoclonal Antibodies Market:
Marketed Brands (US), 2005
Cardiovascular Disorders Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005

Chapter 12

US Therapeutic Monoclonal Antibodies Market for Use in Infectious Diseases
Infectious Diseases Therapeutic Monoclonal Antibodies Market:
Revenue Forecasts (US), 2002-2012
Infectious Diseases Therapeutic Monoclonal Antibodies Market:
Marketed Brands (US), 2005
Infectious Diseases Therapeutic Monoclonal Antibodies Market:
Competitive Structure (US), 2005

List of Charts